Abstract
Great interest exists in standardizing treatment for patients with distal deep vein thrombosis (DDVT), especially regarding the choice of anticoagulant. We evaluated the outcomes for patients with DDVT treated with warfarin vs a direct oral anticoagulant (DOAC) drug (rivaroxaban, apixaban, edoxaban, or dabigatran).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
